Lv22
106 积分 2023-01-10 加入
Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review
4小时前
待确认
Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer
1天前
已完结
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)
1天前
已完结
High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration
12天前
已完结
Subcutaneous rituximab in indolent primary cutaneous B-cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact
22天前
已关闭
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
22天前
已完结
Reversing Transplant Ineligibility With Teclistamab in Ultra–High-Risk Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
22天前
已完结
Subcutaneous rituximab in indolent primary cutaneous B-cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact
22天前
已关闭
Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma
22天前
已完结
Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event
22天前
已完结
皖公网安备34019202002308
